---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-001990"
form_type: "8-K"
ticker: "SABS"
cik: "0001833214"
company_name: "SAB Biotherapeutics, Inc."
filed_at: "2023-01-27T23:59:59+00:00"
generated_at: "2026-06-20T07:21:10.902739+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# SAB Biotherapeutics receives Nasdaq minimum bid price deficiency notice

## Summary
- Received Nasdaq notice on Jan 23, 2023; common stock bid price below $1.00 for 30 consecutive business days.
- Has 180 calendar days (until July 24, 2023) to regain compliance by closing bid price >= $1.00 for 10 consecutive days.
- If not compliant, may apply for additional 180-day period; reverse stock split is a potential cure.
- No immediate effect on listing; company monitoring and evaluating options to regain compliance.
- Failure to regain compliance could lead to delisting from the Nasdaq Global Market.

## SEC filing metadata
- accession: 0001437749-23-001990
- form_type: 8-K
- ticker: SABS
- cik: 0001833214
- company_name: SAB Biotherapeutics, Inc.
- filed_at: 2023-01-27T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1833214/000143774923001990/0001437749-23-001990-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1833214/000143774923001990/sabs20230123_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-001990
- JSON: https://secwatch.observer/filing/0001437749-23-001990.json
- Plain text: https://secwatch.observer/filing/0001437749-23-001990.txt

## Key facts
- Listing & Compliance Notices
  SAB Biotherapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5450(a)(1)
  source text: January 23, 2023, SAB Biotherapeutics, Inc. (the "Company") received a written notification (the “Notice Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that we were not in compliance with Nasdaq Listing Rule 5450(a)(1), as the closing bid price for our common stock was below the $1.00 per share requirement for the last 30 consecutive business days. The Notice Letter stated that we have 180 calendar days, or until July 24, 2023 (the “Initial Compliance Period”), to regain compliance with the minimum bid price requirement. If we do not regain compliance by the end of
  evidence_url: https://www.sec.gov/Archives/edgar/data/1833214/000143774923001990/0001437749-23-001990-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.